Biogen Inc.
$191.44
▲
2.95%
2026-04-22 10:12:13
www.biogen.com
NMS: BIIB
Explore Biogen Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$28.09 B
Current Price
$191.44
52W High / Low
$202.41 / $114.66
Stock P/E
21.83
Book Value
$124.36
Dividend Yield
—
ROCE
9.46%
ROE
7.39%
Face Value
—
EPS
$8.79
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
7,500
Beta
0.16
Debt / Equity
36.47
Current Ratio
2.68
Quick Ratio
2.03
Forward P/E
10.76
Price / Sales
2.57
Enterprise Value
$28.23 B
EV / EBITDA
7.83
EV / Revenue
2.85
Rating
Buy
Target Price
$206.67
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Return on equity is on the weaker side.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | AbbVie Inc. | NOT FOUND | 86.59 | $360.82 B | 3.4% | 22.16% | 62.25% | $244.81 / $168.54 | $-1.85 |
| 2. | Novartis AG | $147.76 | 20.66 | $301.93 B | 3.13% | 21.09% | 30.81% | $131 / $87.89 | $24.18 |
| 3. | Bristol-Myers Squibb Company | $59.38 | 17.16 | $121.36 B | 4.26% | 20.6% | 40.44% | $62.89 / $42.52 | $9.07 |
| 4. | Amgen Inc. | $346.69 | 24.37 | $187.08 B | 2.84% | 13.95% | 1.06% | $391.29 / $261.43 | $16.07 |
| 5. | Merck & Co., Inc. | $112.83 | 15.49 | $278.33 B | 2.9% | 20.37% | 36.88% | $125.14 / $73.31 | $21.26 |
| 6. | Eli Lilly and Company | $921 | 40.12 | $868.52 B | 0.75% | 38.44% | 1.01% | $1,133.95 / $623.78 | $29.66 |
| 7. | Novo Nordisk A/S | $39.12 | 10.82 | $131.02 B | 4.54% | 39.01% | 60.7% | $533.4 / $224.25 | $6.83 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 2.28 B | 2.53 B | 2.65 B | 2.43 B | 2.45 B | — |
| Operating Profit | 385.5 M | 606.5 M | 851.8 M | 625.2 M | 450.6 M | — |
| Net Profit | -48.9 M | 466.5 M | 634.8 M | 240.5 M | 266.7 M | — |
| EPS in Rs | -0.33 | 3.18 | 4.33 | 1.64 | 1.82 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 9.89 B | 9.68 B | 9.84 B | 10.17 B |
| Operating Profit | 2.47 B | 2.28 B | 1.85 B | 2.9 B |
| Net Profit | 1.29 B | 1.63 B | 1.16 B | 3.05 B |
| EPS in Rs | 8.81 | 11.12 | 7.91 | 20.76 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 29.44 B | 28.05 B | 26.84 B | 24.55 B |
| Total Liabilities | 11.18 B | 11.33 B | 12.05 B | 11.17 B |
| Equity | 18.26 B | 16.72 B | 14.8 B | 13.4 B |
| Current Assets | 8.97 B | 7.46 B | 6.86 B | 9.79 B |
| Current Liabilities | 3.35 B | 5.53 B | 3.43 B | 3.27 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 2.2 B | 2.88 B | 1.55 B | 1.38 B |
| Investing CF | -1.37 B | -799.2 M | -4.1 B | 1.58 B |
| Financing CF | -301.9 M | -683.5 M | 149.3 M | -1.75 B |
| Free CF | 1.97 B | 2.52 B | 1.24 B | 1.14 B |
| Capex | -235.4 M | -359.8 M | -311.4 M | -243.2 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -1.62% | -3.32% | — | — |
| Earnings Growth % | 40.57% | -61.89% | — | — |
| Profit Margin % | 16.87% | 11.81% | 29.95% | — |
| Operating Margin % | 23.57% | 18.79% | 28.52% | — |
| Gross Margin % | 76.12% | 74.24% | 77.61% | — |
| EBITDA Margin % | 29.24% | 20.73% | 42.83% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.